Who is affected by this change?

This affects Independence Blue Cross Rheumatology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Oct 1, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.00.62r, Abatacept (Orencia®) for Injection for Intravenous Use

Independence Blue Cross·Rheumatology, Oncology·Pharmacy

Effective date

Oct 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is an update to the policy for Abatacept (Orencia®) injection for intravenous use under the pharmacy category. The policy has been updated for commercial plans with an effective date of October 1, 2025.

Action Required

Action needed

By October 1, 2025: Billing team should review the updated Abatacept (Orencia®) policy at the provided URL to understand any changes to coverage, prior authorization requirements, or billing procedures for this injectable medication. Update billing protocols and prior authorization workflows as needed based on the full policy details.

Related policy hubs

Independence Blue Cross policies Rheumatology Oncology